Quan Zhao
Biographic Data
| ID | 7268608 |
|---|---|
| NAME | Quan Zhao |
| GIVEN NAMES | Quan |
| FAMILY NAME | Zhao |
| SIGNATURE | ZHAO Q |
| AFFILIATIONS | Yuhuangding Hospital |
| ORCID | 0009-0007-1459-2413 |
| VERIFIED | Yes |
| TOTAL WORKS | 4 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 4 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2024 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
Cost-utility analysis of empagliflozin compared with dapagliflozin in patients with type 2 diabetes in China
Background: Empagliflozin, a sodium-glucose cotransporter 2 inhibitor, performs a reduction in the all-cause mortality and cardiovascular mortality in type 2 diabetes mellitus (T2DM) patients compared to dapagliflozin, which has been included in the national volume-based procurement in China. The objective of this study is to evaluate the long-term cost-utility of the addition of empagliflozin (10 mg or 25 mg) versus dapagliflozin (10 mg) in T2DM…
Fengshi gutong capsules attenuates CIA-induced RA bone destruction in rats by targeting TNF-α inhibition
Zhi-Zi-Chi decoction ameliorates depression-like behavior in chronic unpredictable mild stress-induced mice via the PI3K/AKT/mTOR signaling pathway
Cost-utility analysis of add-on vericiguat for the treatment of chronic heart failure with reduced ejection fraction in China
In China, the treatment of CHF with vericiguat is not cost-effective. The drug price could decrease to 145.8 CNY, which could be considered cost-effective
No prominent works on this page.
Cost-utility analysis of add-on vericiguat for the treatment of chronic heart failure with reduced ejection fraction in China
In China, the treatment of CHF with vericiguat is not cost-effective. The drug price could decrease to 145.8 CNY, which could be considered cost-effective
Cost-utility analysis of empagliflozin compared with dapagliflozin in patients with type 2 diabetes in China
Background: Empagliflozin, a sodium-glucose cotransporter 2 inhibitor, performs a reduction in the all-cause mortality and cardiovascular mortality in type 2 diabetes mellitus (T2DM) patients compared to dapagliflozin, which has been included in the national volume-based procurement in China. The objective of this study is to evaluate the long-term cost-utility of the addition of empagliflozin (10 mg or 25 mg) versus dapagliflozin (10 mg) in T2DM…
Fengshi gutong capsules attenuates CIA-induced RA bone destruction in rats by targeting TNF-α inhibition
Zhi-Zi-Chi decoction ameliorates depression-like behavior in chronic unpredictable mild stress-induced mice via the PI3K/AKT/mTOR signaling pathway
Medicine (4 works) · Chemistry (2 works) · China (2 works) · Endocrinology (2 works) · Pharmacology (2 works) · Benzhydryl compounds (1 work) · Biochemistry (1 work) · Biology (1 work) · Biostatistics (1 work) · Bone Metabolism and Diseases (1 work)